

Kristin K. Zorn, MD

106 Winthrop Trail
Little Rock, Arkansas 72211
Cell: (412) 613-4952

KristinZornMD@gmail.com

Education

| | |
|---|-----------|
| Clinical Fellowship in Gynecologic Oncology University of Oklahoma Health Sciences Center Oklahoma City, OK | 7/03-6/05 |
| Research Fellowship in Gynecologic Oncology National Cancer Institute Bethesda, MD | 7/01-6/03 |
| Residency in Obstetrics and Gynecology University of Alabama at Birmingham Birmingham, AL | 7/97-6/01 |
| Doctor of Medicine University of Alabama School of Medicine Birmingham, AL | 8/93-6/97 |
| Bachelor of Arts in History (<i>Magna cum laude</i>) Williams College Williamstown, MA | 9/89-6/93 |

Current Position

| | |
|----------------------------------|--------------|
| Senior Medical Director IQVIA | 3/24-present |
|----------------------------------|--------------|

Professional Experience

| | |
|---|------------|
| Medical Director IQVIA Biotech | 9/21-2/24 |
| Associate Director for Clinical Research Winthrop P. Rockefeller Cancer Institute Little Rock, AR | 7/18-9/21 |
| Director, Hereditary Gynecologic Cancer Clinic University of Arkansas for Medical Sciences | 5/13-9/21 |
| Member, Winthrop P. Rockefeller Cancer Institute | 5/13-9/21 |
| Director, Adult Cancer Genetics Winthrop P. Rockefeller Cancer Institute Little Rock, AR | 1/18-2/21 |
| Director, Division of Gynecologic Oncology University of Arkansas for Medical Sciences | 5/13-1/21 |
| Medical Director, Magee-Womens Hospital High Risk Ovarian Cancer Program Pittsburgh, PA | 11/06-3/13 |
| Member, Magee-Womens Research Institute | 1/08-3/13 |
| Member, University of Pittsburgh Cancer Institute | 6/12-3/13 |

Academic Appointments

| | |
|--|------------|
| Adjunct Professor, Department of Obstetrics and Gynecology University of Arkansas for Medical Sciences Little Rock, AR | 9/21-3/24 |
| Professor, Department of Obstetrics and Gynecology University of Arkansas for Medical Sciences Little Rock, AR | 7/19-9/21 |
| Associate Professor, Division of Genetics University of Arkansas for Medical Sciences | 11/13-9/21 |
| Associate Professor, Obstetrics & Gynecology University of Arkansas for Medical Sciences | 7/13-6/19 |

| | |
|--|--------------|
| Assistant Professor, Obstetrics & Gynecology University of Arkansas for Medical Sciences | 5/13-7/13 |
| Adjunct Assistant Professor Magee-Womens Hospital of UPMC Pittsburgh, PA | 5/13-present |
| Assistant Professor, Obstetrics, Gynecology & Reproductive Sciences Magee-Womens Hospital of UPMC | 8/05-3/13 |

Certification and Licensure

| | |
|--|------|
| Diplomate, American Board of Obstetrics and Gynecology | |
| Obstetrics and Gynecology | 2006 |
| Gynecologic Oncology | 2008 |
| Alabama Medical License (inactive) | 1998 |
| Oklahoma Medical License (inactive) | 2003 |
| Pennsylvania Medical License (inactive) | 2005 |
| Arkansas Medical License | 2013 |

Honors and Awards

| | |
|---|-----------|
| Golden Mug Special Recognition Award | 2020 |
| UAMS Red Sash Teaching Award | 2018 |
| American College of Obstetrics & Gynecology Council on Resident Education National Faculty Teaching Award | 2014 |
| University of Arkansas for Medical Sciences Star Rating | 2017-2018 |
| Top Physician List for Patient Satisfaction | 2016-2017 |
| Circle of Excellence Dean's List | 2013 |
| NIH Women's Reproductive Health Research Career Development Award (K12) | 2010-2012 |
| Program Committee for SGO Annual Meeting | 2004 |
| SGO Annual Meeting President's Award | 2003 |
| Gynecologic Cancer Foundation/Eli Lilly and Company Award for Outstanding Paper by Resident/Fellow at SGO Annual Meeting | 2003 |
| NCI/GCF Fellowship in Gynecologic Oncology | 2001-2003 |
| University of Alabama School of Medicine Chammack Merit Scholarship | 1993-1995 |
| Alpha Omega Alpha | 1996 |
| Dean's Award for Scholarship | 1997 |
| Bruce A. Harris Award for Excellence in Ob/Gyn | 1997 |

Professional Memberships and Activities

| | |
|--|--------------|
| Member, Society of Gynecologic Oncology | 2005-present |
| Member, Board of Directors | 2021 |
| Chair, Communications Committee | 2021 |
| Member, Leadership Institute | 2021 |
| Vice Chair, Communications Committee | 2019-2021 |
| Member, Research and Awards Committee | 2018-2020 |
| Chair, Genetics Working Group | 2013-2018 |
| Member, Nominating Committee | 2012-2013 |
| Member, Marketing and Communications Committee | 2008-2018 |
| - Products and Publications Subcommittee | 2008-2010 |
| - Media Relations Subcommittee | 2010-2018 |
| Member, Coding Committee | 2007-2010 |
| Member, Audit and Investment Committee | 2003-2007 |
| Fellow Representative to Bylaws Committee | 2002-2003 |
| Foundation for Women's Cancer | |
| Member, Board of Directors | 2021 |
| Chair, Communications Committee | 2021 |
| Vice Chair, Communications Committee | 2019-2021 |

| | |
|---|--------------|
| Association of American Cancer Institutes | |
| Member | 2018-2021 |
| Member, CTO Director Forum | 2021 |
| Fellow, American College of Obstetricians and Gynecologists | 2006-present |
| Associate Member, American Association for Cancer Research | 2005-present |
| Member, American Society of Clinical Oncology | 2005-present |

Committee Assignments and Administrative Services

| | |
|---|-----------|
| University of Arkansas for Medical Sciences | |
| Academic Conflict of Interest Committee | |
| Vice Chair | 2021 |
| Member | 2016-2021 |
| Member, Ob/Gyn Department Promotion and Tenure Committee | 2019-2021 |
| Member, Cancer Institute Tissue Use Committee | 2019-2021 |
| Member, Committee for Clinical Research | 2019-2021 |
| Member, Translational Research Institute Leadership Council | 2018-2021 |
| Member, Institutional Conflict of Interest Committee | 2018-2021 |
| Member, Patent and Copyright Committee | 2018-2019 |
| Member, AR-CRIS Governance Committee | 2018-2021 |
| Member, Mammography Guidelines Working Group | 2016-2021 |
| Member, Radiation Oncology Chair Search Committee | 2015-2016 |
| Cancer Institute Disease-Oriented Committee Coordinators' Council | |
| Chair | 2017-2018 |
| Co-chair | 2015-2016 |
| Member, Ob/Gyn Residency Clinical Competency Committee | 2014-2017 |
| Member, Gynecology Process Improvement Committee | 2014-2020 |
| Member, Perioperative Services Committee | 2014-2020 |
| Member, Cancer Service Line Development Committee | 2014 |
| Director, Gynecologic Oncology Disease-Oriented Committee | 2013-2021 |
| NRG Oncology/ Gynecologic Oncology Group | |
| UAMS site | |
| -Principal investigator (full member of NRG) | 2015-2021 |
| -Principal investigator (affiliate of University of Oklahoma) | 2013-2014 |
| Magee-Womens Hospital site | |
| -Principal investigator | 2011-2013 |
| -Co-principal investigator | 2009-2010 |
| Member, Ovarian Cancer Committee | 2012-2021 |
| Member, Committee on Cancer Prevention & Control (CEM liaison) | 2009-2013 |
| Member, Committee on Experimental Medicine/Translational Research | 2007-2021 |
| Aravive Data Safety and Monitoring Committee | |
| Chair, Phase III trial AVB-500-OC-004 | 2021-2023 |
| Member, Phase Ib trial AVB-500-OC-002 | 2018-2020 |
| Arkansas Cervical Cancer Task Force | |
| Member | 2019-2021 |
| University of Pittsburgh | |
| Member, UPCI Clinical Research Oversight Committee | 2010-2013 |
| Member, Molecular Therapeutics & Drug Discovery/Development Program | 2008-2013 |
| Member, Magee-Womens Hospital Tissue Utilization Committee | 2007-2013 |
| Member, Institutional Review Board | 2005-2013 |
| Member, Centers for Disease Control & Prevention HPV Speakers Bureau | 2014-2018 |
| Member, National Cancer Institute Gynecologic Cancer Steering Committee | 2010-2013 |
| NCI Representative to | |
| Gyn Cancer Intergroup Ovarian Cancer Working Group Meeting | 2002 |
| Liaison Committee on Obstetrics & Gynecology Retreat | 2002 |

| | |
|---|--------------|
| Member, National Ovarian Cancer Coalition Medical & Scientific Advisory Board | 2011-present |
| Grant reviewer | |
| Ovarian Cancer Research Foundation | 2011 |
| Kaleidoscope of Hope Foundation | 2009-2013 |
| Translational Research Institution KL2 program | 2019-2021 |

Educational Activities

Continuing Medical Education

| | |
|---|---------------|
| National Cancer Institute Training Institute for Dissemination and Implementation Research in Cancer | 3/2018-7/2018 |
| Harvard School of Public Health Leadership Development for Physicians in Academic Health Centers | 11/2013 |
| National Cancer Institute Molecular Prevention Course | 8/2011 |
| National Cancer Institute Principles and Practice of Cancer Prevention and Control | 7/2011-8/2011 |
| City of Hope Intensive Course in Cancer Risk Assessment | 6/2010-8/2010 |
| SGO Coding Workshop | 9/2006 |
| AACR/ASCO Methods in Clinical Cancer Research Workshop | 7/2006 |

Teaching

| | |
|--|--|
| University of Arkansas for Medical Sciences teaching activities: Medical oncology fellows Residents in the Department of Obstetrics & Gynecology Medical students Physician Assistant students Genetic Counseling students General community | 2013-present |
| University of Pittsburgh teaching activities: Gynecologic oncology, medical oncology, and surgical oncology fellows Residents in the Department of Obstetrics & Gynecology Medical students Physician Assistant students Genetic Counseling students General community | 2005-2013 |
| Special projects: Reorganized MS4 elective in gynecologic oncology Supervised MS4 students on rotation Developed gynecologic cancer lecture for MS4 Neoplasia course Creating "Breaking Bad News Workshop" for residents with Dr. Harrington | 2006 2006-2011 2010-2012 2018 |

Mentees

| | |
|--|--------------|
| Pearman Parker, PhD KL2 mentorship committee member | 2019-2021 |
| Arhita Dasgupta, MS 1-2 medical student Faculty sponsor, Honors in Research Program | 2018-present |
| Amanda Compadre, MS1-4 medical student Faculty sponsor, Honors in Research Program | 2015-present |

| | |
|---|--------------|
| Melinda Simonson, ScM, CGC Mentor, genetic counselor in Hereditary Gynecologic Cancer Clinic | 2015-2021 |
| Teresa Hagan, PhD, RN Member of doctoral advisory committee, advisor for postdoctoral research | 2012-2018 |
| Sarah Taylor, MD Faculty mentor, gyn onc fellowship research External mentor, junior faculty member | 2012-present |
| Ashlee Smith, DO Faculty mentor, gyn onc fellowship research thesis | 2012-2013 |
| Bunja Rungruang, MD Faculty mentor, gyn onc fellowship research thesis | 2011-2012 |

Grants and Contract Awards

Past

| | |
|---|------------|
| Barton Pilot Award PI: Kristin Zorn “Developing a Community-Based Screening Tool for Hereditary Cancer Risk” | 1/1/2021 |
| UAMS Translational Research Institute Pilot Award PTC2020-03 PI: Kristin Zorn “Assessing statewide variation in hereditary cancer care utilization in Arkansas” | 2/1/2020 |
| UAMS Cancer Prevention and Population Sciences Pilot Award PI: Kristin Zorn “Development of a Patient Decision Aid to Support Shared Decision Making About Mammography | 10/1/18 |
| UAMS Translational Research Institute Pilot Award PTC2017-08 PI: Kristin Zorn “An Implementation Strategy to Increase Appropriate Referrals for Genetic Counseling and Testing Among Patients at High Risk for Hereditary Cancer Syndromes” | 11/15/2017 |
| Ovarian Cancer Research Fund Alliance Physician Champion: Kristin Zorn Funding for a Woman to Woman ovarian cancer survivor support group | 7/1/2017 |
| Arkansas Cancer Coalition PI: Kristin Zorn “Improving Access to Cancer Genetic Counseling and Testing Through Telehealth | 7/1/2017 |
| Arkansas Breast Cancer Research Program Award PI: Kristin Zorn “Investigating the Germline Mutation Rate in African-American Women in Arkansas with a Personal or Family History of Breast Cancer Using a Multiplex Panel” | 7/1/2014 |
| Foundation for Gynecologic Oncology Wilma Williams Award PI: Kristin Zorn “Preventing Endometrial Cancer through Outreach to Lynch Syndrome Families” | 1/1/2014 |
| NIH K12 Women’s Reproductive Health Research Award PI: Allen Hogge, MD Scholar: Kristin Zorn, MD | 2010-2013 |

Clinical Trials- active in 2021 (among total of 61 at UAMS)

1. NCI COVID-19 in Cancer Patients (NCCAPS): A longitudinal natural history study **PI: Zorn**
2. Ovarian cancer detection by uterine lavage DNA and serum proteins: A phase 2 biomarker study (EDRN) **PI: Zorn**
3. 3D prediction of patient-specific response using ex vivo interrogation of live cells from tumors (3D PREDICT) **PI: Zorn**
4. NRG GY006 Randomized phase III trial of radiation therapy and cisplatin alone or in combination with intravenous triapine in women with newly diagnosed bulky stage IB2, II, IIIB, or IVA cancer of the uterine cervix or stage II-IVA vaginal cancer **PI: Zorn**
5. NRG GY009 Randomized phase II/III study of pegylated liposomal doxorubicin and CTEP-supplied atezolizumab versus pegylated liposomal doxorubicin/bevacizumab and CTEP-supplied atezolizumab versus pegylated liposomal doxorubicin/bevacizumab in platinum resistant ovarian cancer **PI: Zorn**
6. NRG GY022 Assessment of carboplatin clearance predictors: A PK study on NCI-sponsored clinical trials or standard of care treatments using carboplatin **PI: Zorn**
7. NRG GY019 Randomized phase III, 2-arm trial of paclitaxel/carboplatin/maintenance letrozole versus letrozole monotherapy in patients with stage II-IV, primary low-grade serous carcinoma of the ovary or peritoneum **PI: Zorn**
8. NRG GY012 Randomized phase II study comparing single-agent olaparib, single-agent cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent or metastatic endometrial cancer **PI: Zorn**
9. SWOG S1609 DART: Dual anti-CTLA-4 and anti-PD1 blockade in rare tumors **PI: Zorn**
10. NRG GY006 Randomized phase II trial of radiation therapy and cisplatin alone or in combination with intravenous triapine in women with newly diagnosed, bulky stage IB2, II, IIIB, or IVA cancer of the uterine cervix **PI: Zorn**
11. CTSU AGCT1531 Phase 3 study of active surveillance for low-risk and a randomized trial of carboplatin vs cisplatin for stand risk pediatric and adult patients with germ cell tumors
12. NRG GY005 Randomized phase II/III study of the combination of cediranib and olaparib compared to cediranib or olaparib alone, or standard of care chemotherapy in women with recurrent, platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer **PI: Zorn**
13. NRG GY004 Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer **PI: Zorn**
14. GOG 225 Can diet and exercise modulate ovarian, fallopian tube, and primary peritoneal cancer progression-free survival? **PI: Zorn**
15. GOG 3005 Phase III placebo-controlled study of carboplatin/paclitaxel with or without concurrent and continuation maintenance veliparib in subjects with previously untreated stage III or IV high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer **PI: Zorn**
16. NRG-GOG 274 Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: the Outback trial **PI: Zorn**
17. GOG 286B Randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or stage IVA, IVB or recurrent endometrial cancer **PI: Zorn**
18. GOG 212 Randomized phase III trial of maintenance chemotherapy comparing 12 monthly cycles of single-agent paclitaxel or CT-2103 versus no treatment until documented relapse in women with advanced ovarian or primary peritoneal cancer who achieve a complete clinical response to primary platinum/taxane chemotherapy **PI: Zorn**
19. GOG 252 Phase III clinical trial of bevacizumab with IV versus IP chemotherapy in ovarian, fallopian tube, and primary peritoneal cancer **PI: Zorn**

Editorial Appointments

Guest Editor, *Frontiers in Oncology Research* Topic "Inhibiting PARP as a Strategic Target in Cancer" 2013-2016

Ad hoc reviewer for *Clinical Cancer Research*, *Cancer*, *Cancer Genetics*, *International Journal of Gynecologic Oncology*, and *Gynecologic Oncology*, *PLoS Genetics*, *BMC Cancer* 2004-2021

Publications

MyBibliography available at

<https://www.ncbi.nlm.nih.gov/myncbi/kristin.zorn.1/bibliography/public/>

Peer-reviewed Articles

Mentee/trainee as author underlined

1. Fargason C, **Zorn K**, Ashworth C, Fountain K. Limitations of the current child sexual abuse literature from a Bayesian perspective. *Child Maltreatment* 2:73-77, 1997
2. **Zorn KK**, Jazaeri AA, Awtrey C, Gardner GJ, Mok S, Boyd J, Birrer MJ. Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. *Clin Cancer Research* 9(13):4811-18, 2003. PMID: 14581352
3. Jazaeri AA, Awtrey C, Chandramouli G, Chuang T, Khan J, Sotiriou C, Apelikova O, Yee C, **Zorn KK**, Birrer MJ, Barrett CJ, Body J. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. *Clin Cancer Research* 11(17):6300-10, 2005. PMID: 16144934
4. **Zorn KK**, Bonome T, Gangi L, Chandramouli G, Awtrey C, Gardner GJ, Barrett CJ, Birrer MJ. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. *Clin Cancer Research* 11(18):6422-30, 2005. PMID: 16166416
5. Krivak T and **Zorn KK**. Venous thromboembolism in obstetrics and gynecology. *Obstet Gynecol* 109:761-77, 2007. PMID: 17329532
6. Moore KN, Gold MA, McMeekin DS, **Zorn KK**. Vesicovaginal fistula formation in patients with Stage IVA cervical carcinoma. *Gynecol Oncol* 106 (3):498-501, 2007. PMID: 17561235
7. Dann RB, Kelley JL, **Zorn KK**. Strategies for ovarian cancer prevention. *Obstet Gynecol Clin North Am* 34:667-86, 2007. PMID: 18061863
8. Richard SD, Krivak TC, Beriwal S, **Zorn KK**. Recurrent metastatic vulvar carcinoma treated with cisplatin plus cetuximab. *Int J Gynecol Cancer* 18:1132-35, 2008. PMID: 18021214
9. Moore KN, Gold MA, McMeekin DS, Walker JL, Rutledge T, **Zorn KK**. Extraperitoneal para-aortic lymph node evaluation for cervical cancer via Pfannenstiel incision: technique and perioperative outcomes. *Gynecol Oncol* 108:466-71, 2008. PMID: 18191994
10. Guirguis A, Elishaev E, Oh S, Tseng G, **Zorn K**, Deloia JA. Use of gene expression profiles to stage concurrent endometrioid tumors of the endometrium and ovary. *Gynecol Oncol* 108:370-76, 2008. PMID: 18083218
11. Coon D, Beriwal S, Heron DE, Kelley JL, Edwards RP, Sukumvanich, **Zorn KK**, Krivak TC. High-dose-rate Ratté "Y" applicator brachytherapy for definitive treatment of medically inoperable endometrial cancer: 10-year results. *Int J Radiat Oncol Biol Phys* 71:779-83, 2008. PMID: 18258388
12. Beriwal S, Coon D, Heron DE, Kelley JL, Edwards RP, Sukumvanich P, **Zorn KK**, Krivak TC. Preoperative intensity-modulated radiotherapy and chemotherapy for locally advanced vulvar carcinoma. *Gynecol Oncol* 109:291-95, 2008. PMID: 18455637
13. **Zorn KK**, Tian C, McGuire WP, Hoskins WJ, Markman M, Muggia FM, Rose PG, Ozols RF, Spriggs D, Armstrong DK. The prognostic value of pretreatment CA-125 in advanced ovarian carcinoma: A Gynecologic Oncology Group study. *Cancer* 115:1028-35, 2009. PMID: 19156927; PMCID: PMC2644510
14. Lesnock JL, Richard SD, **Zorn KK**, Krivak TC, Beriwal S, Sukumvanich P, McBee WC, Kelley JL, Edwards RP. Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications. *Gynecol Oncol* 116:345-50, 2010. PMID: 19959211

15. Wegner RE, Beriwal S, Heron DE, Richard SD, Kelley JL, Edwards RP, Sukumvanich P, **Zorn KK**, Krivak TC. Definitive radiation therapy for endometrial cancer in medically inoperable elderly patients. *Brachytherapy* 9:260-65, 2010. PMID: 20122872
16. Gingell D, Samuel A, Haynik D, McBee WC, Kelley J, **Zorn K**, Bhargava R. Metastatic ovarian serous carcinoma presenting as inflammatory breast cancer: a case report. *Int J Gynecol Pathol* 29:243-47, 2010. PMID: 20407323
17. Courtney-Brooks M, Sukumvanich P, Beriwal S, **Zorn KK**, Richard SD, Krivak TC. Does the number of nodes removed impact survival in vulvar cancer patients with node-negative disease? *Gynecol Oncol* 117:308-11, 2010. PMID: 20153883
18. Richard SD, Sukumvanich P, Lesnock JL, McBee WC, Beriwal S, Edwards RP, **Zorn KK**, Krivak TC. Intraperitoneal catheter leads to prolongation of the time to normalization of serum CA125 levels. *Int J Gynecol Cancer* 20:932-35, 2010. PMID: 20683398
19. Rungruang B, Hood BL, Sun M, Hoskins E, Conrads TP, **Zorn KK**. Novel surgical approaches for sampling the ovarian surface epithelium and proximal fluid proteome. *J Proteome Res* 9:6071-76, 2010. PMID: 20873867
20. Skaznik-Wikiel ME, Sukumvanich P, Beriwal S, **Zorn KK**, Kelley JL, Richard S, Krivak TC. Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer. *Int J Gynecol Cancer* 21:1013-17, 2011. PMID: 21792011
21. Skaznik-Wikiel ME, Lesnock JL, McBee WC, Beriwal S, **Zorn KK**, Richard SD, Krivak TC, Edwards RP. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes. *Int J Gynecol Cancer* 22:232-37, 2012. PMID: 22080886
22. Rungruang B, Courtney-Brooks M, Beriwal S, **Zorn KK**, Richard SD, Olawaiye AB, Krivak TC, Sukumvanich P. Surgery versus radiation therapy for stage IB2 cervical carcinoma: a population-based analysis. *Int J Gynecol Cancer* 22:484-89, 2012. PMID: 22249576; PMCID: PMC3190590
23. Dann RB, Deloia JA, Timms KM, **Zorn KK**, Potter J, Flake DD 2nd, Lanchbury JS, Krivak TC. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced ovarian cancer. *Gynecol Oncol* 125:677-82, 2012. PMID: 22406760
24. Engel NJ, Gordon P, Thull D, Dudley B, Herstine J, Jankowitz R, **Zorn KK**. A multidisciplinary clinic for individualizing management of patients at increased risk for breast and gynecologic cancer. *Fam Cancer* 11:419-27, 2012. PMID: 22644142
25. Skaznik-Wikiel ME, Sukumvanich P, Austin RM, **Zorn KK**, Krivak TC, Edwards RP, Olawaiye AB. Heavy cervical cancer burden in elderly women: how can we improve the situation? *Acta Cytol* 56:388-93, 2012. PMID: 22846717
26. The Cancer Genome Atlas Research Network (including **Zorn K**). Integrated genomic characterization of endometrial carcinoma. *Nature* 497:67-73, 2013. PMID: 236363398; PMC3704730
27. Smith AL, Sun M, Bhargava R, Stewart NA, Flint MS, Bigbee WL, Krivak TC, Strange MA, Cooper KL, **Zorn KK**. Proteomic analysis of matched formalin-fixed, paraffin-embedded specimens in patients with advanced serous ovarian carcinoma. *Proteomes* 1:240-253, 2013
28. Berger JL, Smith A, **Zorn KK**, Sukumvanich P, Olawaiye AB, Kelley J, Krivak TC. Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era. *Onco Targets Ther.* 7:1409-13, 2014. Erratum in: *Onco Targets Ther.* 8:593, 2015. PMID: 25143745
29. Taylor SE, Beck TL, Krivak TC, **Zorn KK**, Kelley JL, Edwards RP. Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity. *Gynecol Oncol.* 134:68-72, 2014. PMID: 24769036

30. Perry LJ, Mathews C, Nugent E, Farrell R, **Zorn K**, Moore K. Outcomes of cervical cancer and positive para-aortic lymph nodes in the modern era of chemoradiation, *Int J Gynecol Cancer*. 24:564-9, 2014. PMID: 24552890
31. Taylor SE, Li R, Petschauer JS, Donovan H, O'Neal S, Keeler AW, Zamboni WC, Edwards RP, **Zorn KK**. Phase I study of intravenous docetaxel and intraperitoneal oxaliplatin in recurrent ovarian and fallopian tube cancer. *Gynecol Oncol*. 138:548-53, 2015. PMID: 26111788
32. Hall C, Stone RL, Gehlot A, **Zorn KK**, Burnett AF. Use of metformin in obese women with type I endometrial cancer is associated with a reduced incidence of cancer recurrence. *Int J Gynecol Cancer*. 26:313-17, 2016. PMID: 26588235
33. Silvestri V, *et al* (including **Zorn KK**). Male breast cancer in *BRCA1* and *BRCA2* mutations carriers: pathology data from the Consortium of Investigators of Modifiers of *BRCA1/2*. *Breast Cancer Res*. 18:15, 2016. PMID: 26857456
34. Boisen MM, Lesnock JL, Richard SD, Beriwal S, Kelley JL, **Zorn KK**, Edwards RP. Second-line intraperitoneal platinum-based therapy leads to an increase in second-line progression-free survival for epithelial ovarian cancer. *Int J Gynecol Cancer*. 26:626-31, 2016. PMID: 27051048
35. Rebbeck TR, *et al* (including **Zorn KK**). Inheritance of deleterious mutations at both *BRCA1* and *BRCA2* in an international sample of 32,295 women. *Breast Cancer Res*. 18:112, 2016. PMID: 27836010
36. Hagan TL, Rosenzweig MQ, **Zorn KK**, van London GJ, Donovan HS. Perspectives on self-advocacy: comparing perceived uses, benefits, and drawbacks among survivors and providers. *Oncol Nurs Forum* 44:52-59, 2017. PMID: 28060470
37. Phelan CM, *et al* (including **Zorn KK**). Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nat Genet* 49:680-91, 2017. PMID: 28346442
38. Milne RL, *et al* (including **Zorn KK**). Identification of ten variants associated with risk of estrogen receptor negative breast cancer. *Nat Genet* 49:1767-78, 2017. PMID: 29058716
39. Hagan TL, Cohen SM, Rosenzweig MQ, **Zorn K**, Stone CA, Donovan HS. The female self-advocacy in survivorship scale: a validation study. *J Adv Nurs*. 74:976-87, 2018. PMID: 29117439
40. Rebbeck TR, *et al* (including **Zorn KK**). Mutational spectrum in a worldwide study of 29,700 families with *BRCA1* or *BRCA2* mutations. *Hum Mutat* 39:593-620, 2018. PMID: 29446198
41. Compadre AJ, Simonson ME, Gray K, Runnells G, Kadlubar S, **Zorn KK**. Challenges in recruiting African-American women for a breast cancer genetics study. *Hered Cancer in Clin Pract* 16:8, 2018. PMID: 29760829; PMCID: PMC5937804
42. Lu Y, *et al* (including **Zorn KK**). A transcriptome-wide association study among 97,898 women to identify candidate susceptibility genes for epithelial ovarian cancer risk. *Cancer Res* 78(18):5419-30, 2018. PMID: 30054336; PMCID: PMC6139053
43. Carter NJ, Marshall ML, Susswein LR, **Zorn KK**, Hiraki S, Arvai KJ, Torene RI, McGill AK, Yackowski LY, Murphy OPD, Xu Z, Solomon BD, Klein RT, Hruska KS. Germline pathogenic variants identified in women with ovarian tumor. *Gynecol Oncol* 151(3):481-88, 2018. PMID: 30322717
44. Taylor SE, Donovan H, Zamboni WC, Edwards RP, **Zorn KK**. Phase I study of intravenous (IV) oxaliplatin and intraperitoneal (IP) docetaxel in recurrent ovarian cancer. *Int J Gynecol Cancer* 29:147-52, 2018. PMID: 30640697
45. Jiang X, *et al* (including **Zorn KK**). Shared heritability and functional enrichment across six solid cancers. *Nat Commun* 10:431, 2019. PMID: 30683880; PMCID: PMC6347624. Publisher correction *Nat Commun* 10:4386, 2019. PMID: 31548585
46. Figlioli G, *et al* (including **Zorn KK**). The *FANCM*:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. *NPJ Breast Cancer* 5:38, 2019. PMID: 31700994

47. Taylor SE, Chu T, Elvin JA, Edwards RP, **Zorn KK**. Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer. *Gynecol Oncol* 156:32-37, 2020. PMID: 31739991
48. Patel VL. *et al* (including **Zorn KK**). Association of genomic domains in *BRCA1* and *BRCA2* with prostate cancer risk and aggressiveness. *Cancer Res* 80:624-638, 2020. PMID: 31723001
49. Zhang *et al* (including **Zorn KK**). Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. *Nat Genet* 52:572-581, 2020. PMID: 32424353
50. Silvestri V, *et al* (including **Zorn KK**). Characterization of the cancer spectrum in men with germline *BRCA1* and *BRCA2* pathogenic variants: results from the Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA). *JAMA Oncol* 6:1218-1230, 2020. PMID: 32614418
51. Coignard J, *et al* (including **Zorn KK**). A case-only study to identify genetic modifiers of breast cancer risk for *BRCA1/BRCA2* mutation carriers. *Nat Comm* 12:1078, 2021. PMID: 33537508
52. Parker P, Prabhu AV, Su LJ, **Zorn KK**, *et al*. What's in between the lines: Assessing the readability, understandability, and actionability in breast cancer survivorship print materials. *J Cancer Ed* 2021 Apr 6. doi: 10.1007/s13187-021-02003-4. Online ahead of print. PMID: 33822316
53. Mercier AM, **Zorn KK**, Quick CM, Huffman LB. Recurrent gynandroblastoma of the ovary with germline *DICER1* mutation: A case report and review of the literature. *Gynecol Oncol Rep*. 2021 Jun 7;37:100806. PMID: 34169133
54. Dareng EO, *et al* (including **Zorn KK**). Polygenic risk modeling for prediction of epithelial ovarian cancer risk. *Eur J Hum Genet*. correction 2022 May;30(5):630-631. PMID: 35314806; original publication 2022 Mar;30(3):349-362. PMID: 35027648
55. Acharya M, **Zorn KK**, Simonson ME, *et al*. Statewide trends and factors associated with genetic testing for hereditary cancer risk in Arkansas 2-13-2018. *Hered Cancer Clin Pract* 2022 May 23;20(1):19. PMID: 35606835
56. **Zorn KK**, Simonson ME, Faulkner JL, *et al*. Can automated alerts in the electronic health record encourage referrals for genetic counseling and testing among patients at high risk for hereditary cancer syndromes? *JCO Oncol Pract*. 2022 Jul;18(7): e1219-1224. PMID: 35316088

Invited Manuscripts and Editorials

1. **Zorn KK**. Advancing our understanding of endometrial cancer histologic subtypes: should we lump or split? *Gynecol Oncol* 106:6-7, 2007. PMID: 17574072
2. Stany MP, Bonome T, Wamunyokoli F, **Zorn K**, Ozbun L, Park DC, Hao K, Boyd J, Sood AK, Gershenson DM, Berkowitz RS, Mok SC, Birrer MJ. Classification of ovarian cancer: a genomic analysis. *Adv Exp Med Bioi* 622:23-33, 2008. PMID: 18546616
3. Dumrongpakapakorn P, Hopkins K, Sherwood P, **Zorn K**, Donovan H. Computer-mediated patient education: opportunities and challenges for supporting women with ovarian cancer. *Nurs Clin N Am* 44:339-54, 2009. PMID: 19683095
4. **Zorn KK**. Challenges to the paclitaxel/carboplatin algorithm in ovarian cancer treatment. *Oncology* 24:738-740, 2010. PMID: 20718253
5. **Zorn KK**. PARP inhibition in epithelial ovarian cancer: high hopes undergo a reality check. *Oncology* 26:128-136, 2012. PMID: 22489345
6. **Zorn KK**, Annunziata CM. Inhibiting PARP as a strategic target in cancer. *Front Oncol* 6:91, 2016. PMID: 27148483
7. Moore KN, **Zorn KK**. Germline and somatic testing in ovarian cancer: Shifting sands of recommendations. *Gynecol Oncol*. 156(3):515-516, 2020. PMID: 32127132

8. **Zorn KK**, Birrer M. PARP inhibitor therapy options are transforming landscape in ovarian cancer. OncLive September 4, 2020.

Book Chapters

1. **Zorn KK**, Gardner GJ, Birrer MJ. The biology of gynecologic cancer. In: Hoskins WJ, ed. Principles and Practice of Gynecologic Oncology, 2004
2. **Zorn KK**, Gardner GJ, Birrer MJ. The chemoprevention of epithelial ovarian cancer. In: Kelloff GJ, ed. Strategies for Cancer Chemoprevention, 2005
3. Birrer MJ, **Zorn KK**, Gardner GJ. Molecular profiling in ovarian cancer. In: Levenback CF, ed. Prognostic and Predictive Factors in Gynecologic Cancers, 2007
4. **Zorn KK**, Gardner GJ, Farley JH, Birrer MJ. The biology of gynecologic cancer. In: Barakat RR, ed. Principles and Practice of Gynecologic Oncology, 2009
5. Smith A, **Zorn KK**. Vulvar Cancer. In: Biegi RH, ed. Sexually Transmitted Diseases, 2012

Abstracts and Presentations

** invited presentation*

Mentee as first author underlined

Oral Presentations

National Meetings

1. **Zorn KK**. The role of genetic testing in gynecologic cancer treatment and prevention. SGO Allied Health Professionals Meeting, Chicago, IL. 2019*
2. Simonson ME, Compadre AJ, Gray K, **Zorn KK**. Analysis of family history in African-American women in a breast cancer genetics study. American College of Medical Genetics and Genomics, Charlotte, NC. 2018
3. **Zorn KK**. Incorporating genetic evaluation in your practice. American Congress of Obstetricians and Gynecologists, San Francisco, CA. 2015*
4. **Zorn KK**. Targeting genetic defects in DNA repair in ovarian cancer. Society of Gynecologic Oncology Annual Meeting, Chicago, IL. 2015*
5. **Zorn KK**. Ovarian cancer: a disease of DNA repair? Gynecologic Oncology Group Summer Scientific Session, Boston, MA. 2012*
6. **Zorn KK**. Lessons we've learned about ovarian cancer development from high-risk women. Ovarian Cancer: Prevention, Detection, and Treatment Symposium, Pittsburgh, PA. 2012*
7. **Zorn KK**, Rungruang B, Hood BL, Sun M, Hoskins E, Conrads TP. Proteomic analysis of pelvic tissues collected during risk-reducing surgery in *BRCA* mutation carriers. Women's Reproductive Health Research Symposium, Providence, RI. 2011
8. **Zorn KK**. The struggle to practice evidence-based medicine in gynecologic oncology. Mid-Atlantic Gynecologic Oncology Society Annual Meeting Keynote Presentation, Hot Springs, VA. 2009*
9. **Zorn KK**, Tian C, McGuire WP, Hoskins WJ, Markman M, Muggia FM, Rose PG, Ozols RF, Spriggs D, Armstrong DK. Significance of pretreatment CA-125 level in advanced ovarian carcinoma: a combined analysis of seven Gynecologic Oncology Group protocols. Society of Gynecologic Oncologists, San Diego, CA. 2007

10. **Zorn KK.** Molecular biology of mucinous and clear cell carcinoma. Gynecologic Oncology Group Winter Meeting Symposium, San Diego, CA. 2007*
11. **Zorn KK.** Adhesion barriers and intraperitoneal chemotherapy. International Symposium on Regional Cancer Therapies, Puerto Rico, 2007*
12. **Zorn KK,** Moore KN, Gold MA, McMeekin DS. Fistula formation in patients with stage IVA cervical carcinoma. Western Association of Gynecologic Oncologists, Santa Fe, NM. 2005
13. **Zorn KK,** Moore KN, Gold MA, McMeekin DS. Survival in patients with cervical cancer metastatic to the para-aortic lymph nodes. Western Association of Gynecologic Oncologists, Santa Fe, NM. 2005
14. **Zorn KK,** Bonome T, Gangi L, Chandramouli G, Awtrey C, Gardner GJ, Barrett CJ, Birrer MJ. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Society of Gynecologic Oncologists, New Orleans, 2003
15. **Zorn K,** Fargason C, Ashworth C, Fountain K. Test characteristics of the physical examination in sexual assault. Southern Society for Pediatric Research, New Orleans, LA. 1995

Local/Regional Meetings

16. COVID-19 vaccination for patients with cancer. Family Medicine Update, Little Rock, AR. 10/26/21*
17. Faculty Excellence Lecture Series panel discussion: Team science: pairing clinicians with scientists. Little Rock, AR. 5/19/21*
18. COVID-19 vaccination for patients with cancer. Arkansas Cancer Coalition Quarterly Meeting, Little Rock, AR. 5/11/21*
19. Delivering bad news. Joint workshop for UAMS ob/gyn residents and faculty with palliative care. Little Rock, AR. 4/28/21*
20. If HPV vaccination prevents cancer, why don't more teens get vaccinated? HPV Summit for Medical and Dental Professionals, Little Rock, AR. 5/1/20*
21. Update on genetic testing for hereditary cancer syndromes. Obstetrics and Gynecology Grand Rounds. University of Arkansas for Medical Sciences, Little Rock, AR. 12/4/19
22. The role of cancer genetic testing in geriatric patients. Geriatrics Grand Rounds. University of Arkansas for Medical Sciences, Little Rock, AR. 10/15/19*
23. The role of genetic testing in gynecologic cancer. Kappa Epsilon Pharmacy Fraternity, Little Rock, AR. 10/1/19 *
24. Hereditary risk for gastrointestinal cancer. Southeastern Colorectal Cancer Consortium Conference, Little Rock, AR. 6/20/19*
25. The role of genetic testing in cancer treatment and prevention. Little Rock Oncologist Nursing Society Spring Oncology Update, Little Rock, AR. 3/7/19*
26. The burden of HPV-related cancer: a patient's story. HPV Summit for Medical and Dental Professionals, Little Rock, AR. 3/1/19*
27. Update on cervical and ovarian cancer. UAMS Regional Program, Jonesboro, AR. 12/4/18*
28. Community engaged researchers meeting panel discussion. UAMS Translational Research Institute, Little Rock, AR. 10/11/18*
29. Delivering bad news. Joint workshop for UAMS ob/gyn residents and faculty with palliative care. Little Rock, AR. 10/10/18*

30. Endometrial and ovarian cancer update. Christus St. Michael Tumor Board, Texarkana, TX. 7/20/18*
31. The role of genetic testing. Woman to Woman Peer Support Group, Little Rock, AR. 6/12/18*
32. Hereditary considerations in gynecologic cancer: from oddity to standard of care. Magee-Womens Hospital Katz Lecture, Pittsburgh, PA. 5/15/18*
33. Incorporating genetics into gynecologic cancer care: a change in the standard of care. 40th Annual Family Medicine Intensive Review Course, Little Rock, AR. 5/10/18*
34. The medical provider perspective on distress in cancer patients. Arkansas Igniting Distress research and care through Engagement and Actions (AR IDEAs), Little Rock, AR. 5/5/18*
35. The HPV connection to cancer. Arkansas Immunization Coalition 2018 HPV Summit, Little Rock, AR. 5/4/18*
36. Update on cancer genetics and gynecologic oncology. Winthrop P. Rockefeller Cancer Institute Board of Directors, Little Rock, AR. 5/3/18*
37. Cancer prevention update with focus on HPV vaccination and genetic testing. Arkansas Cancer Summit, Little Rock, AR. 3/13/18*
38. Using telehealth to address cancer disparities. Winthrop P. Rockefeller Cancer Institute Cancer Prevention and Population Science Retreat, Little Rock, AR. 9/22/17*
39. Improving access to cancer genetic counseling and testing through telehealth. Arkansas Cancer Coalition Quarterly Meeting, Little Rock, AR. 9/12/17*
40. Improving access to cancer genetic counseling and testing. Connecting Across Professions Lecture Series, University of Arkansas for Medical Sciences, Little Rock, AR. 8/23/17
41. Current Management of ovarian cancer. Arkansas Medical, Dental, and Pharmaceutical Association, Little Rock, AR. 6/10/17*
42. HPV vaccination is cancer prevention. Winthrop P. Rockefeller Cancer Institute Grand Rounds, Little Rock, AR. 1/25/17
43. Cancer genetics- expanding our reach beyond Little Rock. Translational Research Institute Community Review Board, Texarkana, AR. 1/24/17
44. HPV vaccination update, Obstetrics and Gynecology Grand Rounds. University of Arkansas for Medical Sciences, Little Rock, AR. 11/9/16
45. Gynecologic cancer. Department of Physician Assistant Studies, University of Arkansas for Medical Sciences, Little Rock, AR. 3/29/16*
46. Gynecologic cancer prevention and hereditary gynecologic cancer. 30th Annual Arkansas Osteopathic Medical Association State Convention, Branson, MO. 8/14/15*
47. You are the key to HPV cancer prevention. 37th Annual Family Medicine Intensive Review Course, Department of Family and Preventive Medicine, University of Arkansas for Medical Sciences, Little Rock, AR. 5/15/15*
48. Gynecologic cancer. Department of Physician Assistant Studies, University of Arkansas for Medical Sciences, Little Rock, AR. 4/3/15*
49. You are the key to HPV cancer prevention. Department of Pediatrics Grand Rounds, Arkansas Children's Hospital, Little Rock, AR. 1/23/15
50. Update on HPV vaccination. Obstetrics and Gynecology Grand Rounds, University of Arkansas for Medical Sciences, Little Rock, AR. 11/5/14

51. You are the key to HPV cancer prevention. Winthrop P. Rockefeller Cancer Institute Grand Rounds, Little Rock, AR. 9/10/14
52. Update on gynecologic cancer. Zook Oncology Nursing Symposium, Department of Nursing, University of Arkansas for Medical Sciences, Little Rock, AR. 8/8/14*
53. Ovarian cancer prevention and screening. 36th Annual Family Medicine Intensive Review Course, Department of Family and Preventive Medicine, University of Arkansas for Medical Sciences. 5/15/14*
54. Gynecologic cancer. Department of Physician Assistant Studies, University of Arkansas for Medical Sciences, Little Rock, AR. 4/4/14*
55. Update on gynecologic cancer. Women's Health Update 3rd Annual Conference, UAMS Center for Distance Health, Little Rock, AR. 9/27/13*
56. Update on cervical cancer. Area Health Education Center Lecture Series, Jonesboro, AR. 8/3/13*
57. Hereditary gynecologic cancer. Winthrop P. Rockefeller Cancer Institute Grand Rounds, University of Arkansas for Medical Sciences, Little Rock, AR. 7/31/13
58. Hereditary gynecologic cancer. Obstetrics and Gynecology Grand Rounds University of Arkansas for Medical Sciences, Little Rock, AR. 1/23/13
59. Managing hereditary risk for gynecologic cancer. Magee-Womens Hospital Grand Rounds. 6/19/12
60. Assessing hereditary risk for ovarian cancer. Georgia Health Sciences University Obstetrics and Gynecology Grand Rounds. 6/13/12*
61. Management of ovarian cancer risk in women with *BRCA1/2* mutations. 4th Annual UPMC Symposium on Hereditary Cancers, Pittsburgh, PA. 2011*
62. Highlights from ASCO 2011: Focus on ovarian cancer. The Institute for Continuing Healthcare Education. Presentations in Los Angeles, Chicago, and Pittsburgh. Fall 2011*
63. Rational targets for the prevention of gynecologic cancer. UPMC McKeesport Grand Rounds. 4/19/11
64. Can salpingectomy replace salpingo-oophorectomy for gynecologic cancer risk reduction in hereditary breast and ovarian cancer syndrome? City of Hope Topics in Cancer Genetics Research. 2/11/11
65. How to approach ovarian cancer patients with possible *BRCA1* and *BRCA2* mutations. UPMC Hereditary Cancers Conference, Pittsburgh, PA. 2009*
66. What can women at high genetic risk teach us about the pathogenesis of ovarian, fallopian tube, and primary peritoneal cancer? Fox Chase Cancer Center Seminar, Philadelphia, PA. 12/4/07
67. HNPCC and gynecologic cancer risk. UPMC Hereditary Cancers Conference, Pittsburgh, PA. 2007*
68. Update on the HPV vaccine. St. Clair Hospital Grand Rounds, Pittsburgh, PA. 2/21/07
69. Gynecologic cancers- the latest developments from recognizing signs and symptoms to post-operative care. Conemaugh Health System, Johnstown, PA. 5/4/06
70. Intraperitoneal chemotherapy for ovarian cancer. Magee-Womens Hospital Grand Rounds. 1/31/06
71. Cervical cancer: recent advances in diagnosis and treatment. Magee-Womens Hospital Update in Gynecologic Oncology, Pittsburgh, PA. 11/18/05
72. Surgical care of the geriatric patient. University of Oklahoma Medical Center Ob/Gyn Grand Rounds. 7/23/04
73. Molecularly targeted therapies: a story of two drugs. University of Oklahoma Health Sciences Center Ob/Gyn Grand Rounds. 11/7/03

Other Invited Lectures

1. Genetics and ovarian cancer. CancerCare Teleconference. 3/5/19
2. Community participation in medical research. Unitarian Universalist Church, Little Rock, AR. 4/29/18
3. Enhancing access to cancer genetic counseling and testing in Arkansas. UAMS Envoys Lecture Series, Little Rock, AR. 3/15/18
4. Genetics and gynecologic cancer. Foundation for Women's Cancer Survivor Course, Oklahoma City, OK. 8/27/16
5. Genetics and gynecologic cancer. Ovarian Cancer National Conference, Washington, D.C. 7/10/16
6. Women in surgery panel for first and second year medical students. University of Arkansas for Medical Sciences, Little Rock, AR. 3/29/16
7. Ovarian cancer update. CancerCare Teleconference. 4/28/15
8. Ovarian cancer & genetics. Wig Boutique Dedication, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences. 1/27/14
9. Understanding genetic risk for ovarian cancer. National Ovarian Cancer Coalition national meeting, Las Vegas, NV. 11/9/12
10. Understanding genetic risk for ovarian cancer. Youngstown Jewish Community Center in honor of the Rose Mary Flanagan Ovarian Cancer Foundation. 10/9/12
11. Gynecologic cancer research update. Live Well Survivorship Workshop, Monroeville, PA. 9/11/12
12. Understanding genetic risk for ovarian cancer. National Ovarian Cancer Coalition Pittsburgh chapter meeting. 10/5/11
13. Gynecologic cancer research update. Magee-Womens Hospital Cancer Survivors Wellness Workshop. 9/14/10
14. Preparing for the oral oncology boards. Society of Gynecologic Oncologists Annual Meeting, San Francisco, CA. 3/15/10
15. Gynecologic cancer research update. Magee-Womens Hospital Cancer Survivors Wellness Workshop. 9/17/09
16. Hereditary gynecologic cancer research at Magee. National Council of Jewish Women, Pittsburgh, PA. 3/25/09
17. Subspecialty choices in Ob/Gyn. University of Pittsburgh School of Medicine Med Student Ob/Gyn Interest Group, Pittsburgh, PA. 2/19/09
18. Personalizing treatment of ovarian cancer and managing risk for developing ovarian cancer. Magee-Womens Foundation Gynecologic Cancer Research Update, Pittsburgh, PA. 6/26/08
19. Managing genetic risk for ovarian cancer: Is "when in doubt, cut them out" the right strategy? Magee-Womens Research Foundation Lunch and Learn Series, Pittsburgh, PA. 4/15/08
20. Management of women at high risk for gynecologic cancer. UPMC Women's Health Seminar Series, Pittsburgh, PA. 11/5/07
21. Clinical innovations in ovarian cancer treatment. National Ovarian Cancer Coalition, Pittsburgh, PA. 7/11/07
22. Update on gynecologic cancer. Cameron Wellness Center, Pittsburgh, PA. 5/31/07
23. Update on the HPV vaccine. Mother-Daughter Tea at Hillman Cancer Center, Pittsburgh, PA. 5/5/07

24. Update on gynecologic cancers. Soroptimist International of the Americas Regional Meeting, Pittsburgh, PA. 10/28/06
25. Intraperitoneal therapy in ovarian cancer. National Ovarian Cancer Coalition, Pittsburgh, PA. 2/6/06

Posters

National/International Meetings

1. Simonson ME, Acuna J, Jenkins J, Hall T, Carr C, **Zorn KK**. Use of an EMR-based tool for identification and referral of patients eligible for cancer genetic counseling at an academic cancer center. National Society of Genetic Counselors Annual Conference, Salt Lake City, UT. 2019
2. **Zorn KK**, Simonson ME, Compadre A, Gray K, Runnells GA, Harrell MI, Gulsuner S, Radke M, Swisher EM. Germline mutation rate in African-American women in Arkansas with a personal and/or family history of breast cancer. Society of Gynecologic Oncology, New Orleans, LA. 2018
3. Burnett AF, Huffman LB, Quick CM, Savage JE, **Zorn KK**. Should ovaries be conserved in low-risk endometrial cancer? Society of Gynecologic Oncology, New Orleans, LA. 2018
4. Gornet BA, Thompson C, Ojalvo L, Nickles-Fader A, Tanner E, Berger J, Sullivan S, Gunderson C, Acuna J, **Zorn K**, Burnett A, Carey S, Stone R. Contemporary recurrence and survival outcomes for stage IB squamous cell carcinoma of the vulva: time to raise the bar. Society of Gynecologic Oncology, National Harbor, DC. 2017
5. Taylor SE, Chu T, Edwards RP, **Zorn KK**. Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer. American Society of Clinical Oncology, Chicago, IL. 2016
6. Compadre AJ, Simonson ME, Gray K, **Zorn KK**. Challenges to recruiting African-American women to participate in a breast cancer genetic testing study. Sixth International Symposium on Hereditary Breast and Ovarian Cancer, Montreal, Canada. 2016
7. Taylor SE, Li R, Petschauer JS, Donovan HD, Zamboni WC, Edwards RP, **Zorn KK**. Phase I study of intravenous oxaliplatin and intraperitoneal docetaxel in recurrent ovarian and primary peritoneal cancer. Society of Gynecologic Oncology, Chicago, IL. 2015
8. Taylor SE, Li Rousha, Petschauer JS, Donovan Heidi, Zamboni WC, Edwards RP, **Zorn K**. Phase I study of intravenous docetaxel and intraperitoneal oxaliplatin in recurrent ovarian, fallopian tube and peritoneal cancer. American Association for Cancer Research, San Diego, CA. 2014
9. Smith A, Sun M, Bhargava R, Stewart N, Flint M, Krivak T, Strange M, Bigbee W, Yates N, **Zorn K**. Proteomic analysis of matched formalin-fixed, paraffin-embedded specimens in patients with advanced serous ovarian carcinoma. Society of Gynecologic Oncology, Los Angeles, CA. 2013
10. Hinshaw H, Engel N, Sampene E, **Zorn K**. Ten-year experience with a multidisciplinary high-risk program. Society of Gynecologic Oncology, Los Angeles, CA. 2013
11. Taylor S, Beck T, Krivak T, **Zorn K**, Kelley J, Edwards R. Successful oxaliplatin salvage for recurrent ovarian cancer after carboplatin/cisplatin allergy. Society of Gynecologic Oncology, Los Angeles, CA. 2013
12. Rowland M, Lesnock J, Edwards R, Richard S, **Zorn K**, Sukumvanich P, Krivak T. Occult uterine cancer in patients undergoing laparoscopic hysterectomy with morcellation: Implications for surveillance for disease recurrence and outcomes. Society of Gynecologic Oncology, Los Angeles, CA. 2013
13. **Zorn KK**, Zeng X, Sun M, Jones-Laughner J, Stewart N, Flint MS, Conrads TP, Bigbee WL, Yates N. Proteomic analysis of pelvic tissues collected during risk-reducing surgery in *BRCA* mutation carriers. Women's Reproductive Health Research Symposium, Philadelphia, PA. 2012

14. Hansen K, Lin J, Beriwal S, Kelley J, Krivak T, Edwards R, Richard S, Olawaiye A, **Zorn K**, Sukumvanich P. A population-based study on postoperative outcomes of pelvic exenteration for gynecologic cancers. Society of Gynecologic Oncology, Austin, TX. 2012
15. Boisen M, Lesnock, J, Sukumvanich P, Beriwal S, Austin R, Kelley J, **Zorn K**, Krivak T, Olawaiye A. The risk for omental metastases and the impact on overall survival in patients with uterine papillary serous and clear cell endometrial cancer. Society of Gynecologic Oncology, Austin, TX. 2012
16. Hansen K, Lin J, Beriwal S, Lesnock J, Sukumvanich P, RichardS, Olawaiye A, Kelley J, **Zorn K**, Krivak T. Impact of postoperative treatment on stage IIIC endometrial cancer: a comparison of single modality to multimodality therapy. Society of Gynecologic Oncology, Austin, TX. 2012
17. Boisen M, Lesnock J, McBee W, RichardS, Kelley J, **Zorn K**, Krivak T, Edwards R. CA125 surveillance and second-line intraperitoneal platinum-based therapy increases second-line progression-free survival for epithelial ovarian cancer. Society of Gynecologic Oncology, Austin, TX. 2012
18. Taylor S, Keley J, Rauh-Hain J, Boisen M, Sukumvanich P, Richard S, **Zorn K**, Christopherson W, Krivak T, Olawaiye A. An assessment of risk factors for superficial surgical site infection and superficial wound separation in gynecologic oncology patients. Society of Gynecologic Oncology, Austin, TX. 2012
19. Laskey R, RichardS, Smith A, Lesnock J, **Zorn K**, Sukumvanich P, Kelley J, Olawaiye A, Krivak T. Retreatment with bevacizumab in patients with recurrent ovarian cancer does not increase morbidity and has a favorable response. Society of Gynecologic Oncology, Austin, TX. 2012
20. Skaznik-Wikiel ME, Lesnock J, McBee WC, Richard SO, Kelley JL, **Zorn KK**, Krivak TC, Edwards RP. Extended duration of response with second-line intraperitoneal platinum-based therapy for epithelial ovarian cancer. American Society of Clinical Oncology, Chicago, IL. 2011
21. **Zorn KK**, Rungruang B, Hood BL, Sun M, Chivukula M, Nikiforova M, Conrads TP. Proteomic analysis of pelvic tissues collected at the time of risk-reducing surgery in *BRCA* mutation carriers. American Association for Cancer Research, Orlando, FL. 2011
22. Skaznik-Wikiel ME, Lesnock J, McBee WC, TaylorS, Beriwal S, Smith A, **Zorn K**, Richard S, Krivak TC, Edwards RP. Intraperitoneal chemotherapy for recurrent ovarian cancer appears efficacious with high completion rates and low complications. Society of Gynecologic Oncologists, Orlando, FL. 2011
23. Roque D, Rungruang B, Thaller J, Vlad A, Mantia-Smaldone G, Goldman H, Chu T, **Zorn K**, Edwards R. Intraperitoneal catheter aspirates can be used to monitor tumor microenvironment biomarkers. Society of Gynecologic Oncologists, San Francisco, CA. 2010
24. Lesnock J, Chu T, RichardS, Kubenik M, Krivak T, **Zorn K**, Sukumvanich P, Kelley J, Edwards R. Impact of modification of the standard intraperitoneal paclitaxel/cisplatin chemotherapy regimen on progression-free survival. Society of Gynecologic Oncologists, San Francisco, CA. 2010
25. **Zorn K**, Donovan H, Zamboni W, Edwards R. Phase I trial of intravenous docetaxel and intraperitoneal oxaliplatin in recurrent ovarian, fallopian tube, and primary peritoneal cancer. Society of Gynecologic Oncologists, San Francisco, CA. 2010
26. Byler Dann, R, DeLoia J, Timms K, **Zorn K**, Potter J, FlakeD, Krivak T. Frequency of *BRCA1* and *BRCA2* mutations in tumors of patients with epithelial ovarian cancer. Society of Gynecologic Oncologists, San Francisco, CA. 2010
27. Mantia-Smaldone G, Budi R, Mansuria S, Lee T, **Zorn K**, Elishaev E, Edwards R, Vlad A. Immune regulation in endometriosis and epithelial ovarian cancer. Society of Gynecologic Oncologists, San Francisco, CA. 2010
28. Beck T, Sukumvanich P, Rubatt J, Beriwal S, **Zorn K**, Richard S, Edwards R, Krivak T. Impact of the National Cancer Institute's clinical announcement on cervical cancer survival. Society of Gynecologic Oncologists, San Francisco, CA. 2010

29. Courtney-Brooks M, Rungruang B, Beriwal S, **Zorn K**, Richard S, Sukumvanich P, Olawaiye A, Krivak T. Surgery versus radiation therapy for stage IB2 cervical carcinoma: a population-based outcome analysis in the era of chemoradiation. Society of Gynecologic Oncologists, San Francisco, CA. 2010
30. McBee WC, Richard SO, Lesnock J, Sukumvanich P, **Zorn KK**, Edwards RP, Krivak TC. Large bowel resection may limit the ability to complete intraperitoneal chemotherapy. Society of Gynecologic Oncologists, San Antonio, TX. 2009
31. Lesnock J, Sukumvanich P, Krivak TC, Richard SO, Beriwal S, Edwards RP, Kelley JL, **Zorn KK**. Is there a role for chemotherapy beyond second-line regimens? Society of Gynecologic Oncologists, San Antonio, TX. 2009
32. Richard SO, McBee WC, Lesnock J, Sukumvanich P, **Zorn KK**, Edwards RP, Krivak TC. Does age affect completion rates for intraperitoneal chemotherapy? Society of Gynecologic Oncologists, San Antonio, TX. 2009
33. McBee WC, Richard SO, Edwards RP, **Zorn KK**, Lesnock J, Sukumvanich P, Krivak TC. Comparison of completion rates for intraperitoneal chemotherapy in front-line and consolidation therapy for ovarian carcinoma. Society of Gynecologic Oncologists, San Antonio, TX. 2009
34. Courtney-Brooks M, Beriwal S, **Zorn KK**, Richard SO, Sukumvanich P. Does the number of nodes removed impact survival in patients with node-negative vulvar cancer? Society of Gynecologic Oncologists, San Antonio, TX. 2009
35. Byler Dann RJ, Krivak TC, Kelley JL, **Zorn KK**, Beriwal S. Salvage of residual or recurrent para-aortic nodal disease secondary to endometrial cancer using intensity-modulated radiation therapy. Society of Gynecologic Oncologists, San Antonio, TX. 2009
36. Lesnock J, Richard SO, McBee WC, Sukumvanich P, **Zorn KK**, Edwards RP, Krivak TC. Completion of intraperitoneal chemotherapy is not catheter-related: a comparison of 2 catheter types. Society of Gynecologic Oncologists, San Antonio, TX. 2009
37. Lesnock J, Richard SO, McBee WC, **Zorn KK**, Sukumvanich P, Edwards RP, Krivak TC. A modification of the standard intraperitoneal paclitaxel/cisplatin chemotherapy regimen results in higher completion rates. Society of Gynecologic Oncologists, San Antonio, TX. 2009
38. Landrum LM, Gold MA, Moore KN, **Zorn KK**, McMeekin S, Walker JL, Zuna R. Adenocarcinoma of the cervix: Evaluation of human papillomavirus genotyping and outcome measures at a single institution. Society of Gynecologic Oncologists, San Antonio, TX. 2009
39. Richard SD, Lesnock J, Sukumvanich P, **Zorn KK**, Edwards RP, Kelley JL, Dann RB, Krivak TC. Intraperitoneal catheter may prolong the time to normalization of CA-125 levels. Society of Gynecologic Oncologists, Tampa, FL. 2008
40. Beriwal S, Coon D, Heron DE, Kelley JL, Edwards RP, Sukumvanich P, **Zorn KK**, Krivak TC. Preoperative intensity-modulated radiotherapy and chemotherapy for locally advanced vulvar carcinoma. Society of Gynecologic Oncologists, Tampa, FL. 2008
41. Guirguis A, **Zorn KK**, Elishaev E, Oh S, Tseng G, DeLoia J. Characterization of simultaneous ovarian and endometrial carcinoma by copy number analysis. American Association for Cancer Research, Los Angeles, CA. 2007
42. Richard S, Krivak TC, Kelley JL, **Zorn KK**, Sukumvanich P, Edwards RP. Termination of intraperitoneal chemotherapy is driven by treatment toxicity rather than catheter dysfunction. American Society of Clinical Oncology, Chicago, IL. 2007
43. Guirguis A, **Zorn KK**, Elishaev E, Oh S, Tseng G, DeLoia J. Can gene expression signatures discriminate between endometrioid carcinomas of ovarian and endometrial origin? Society of Gynecologic Oncologists, San Diego, CA. 2007
44. Castleberry A, Beriwal S, **Zorn KK**, Krivak TC, Kelley JL, Edwards RP, Sukumvanich P. Impact of race on outcomes in cervical and vaginal cancer, Society of Gynecologic Oncologists, San Diego, CA. 2007

45. Richard S, Krivak TC, Kelley JL, **Zorn KK**, Sukumvanich P, Edwards RP. Termination of intraperitoneal chemotherapy is driven by treatment toxicity rather than catheter dysfunction. International Symposium on Regional Cancer Therapies, San Juan, PR. 2007
46. Gardner GJ, **Zorn KK**, Rothschild J, Leaner V, Szabo E, Birrer MJ. Cytotoxicity in ovarian cancer cells is induced by oral hypoglycemic agents. Society of Gynecologic Oncologists. New Orleans, LA. 2003
47. **Zorn KK**, Awtrey A, Gardner G, Barrett JC, Boyd J, Birrer MJ. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. American Association for Cancer Research. Toronto, Canada. 2003
48. Gardner GJ, **Zorn KK**, Rothschild J, Szabo E, Birrer MJ. Peroxisome proliferators activated receptor gamma ligands inhibit ovarian cancer cell growth. American Association for Cancer Research. San Francisco, CA. 2002
49. **Zorn KK**, Gardner GJ, Jazaeri AA, Mok S, Birrer MJ. Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer microarray studies. Oncogenomics. Dublin, Ireland. 2002
50. Vanderkwaak T, **Zorn KK**, Dumas G, Barnes M, Austin J, Alvarez R, Partridge E. Long-term follow-up of patients with negative second look laparotomy after initial therapy with paclitaxel/platinum chemotherapy. Society of Gynecologic Oncologists. San Diego, CA. 2000

Local/Regional Meetings

51. Dasgupta A, Simonson ME, Acuna J, Compadre A, Bimali M, Runnels GA, Su J, Kadlubar SA, **Zorn KK**. Levels of disadvantage in African-American participants of Spit for the Cure. UAMS Student Research Day, Little Rock, AR. 2019
52. Dasgupta A, Simonson ME, Acuna J, Compadre A, Runnels GA, Kadlubar SA, **Zorn KK**. Levels of disadvantage in African-American participants in SFTC biorepository. ABI Fall Research Symposium, Little Rock, AR. 2018
53. Compadre AJ, Simonson ME, Gray K, **Zorn KK**. Challenges to recruiting African-American women to participate in a breast cancer genetic testing study. University of Arkansas for Medical Sciences Student Research Day, Little Rock, AR. 2016
54. Rowland M, Lesnock J, Edwards R, Richard S, **Zorn K**, Sukumvanich P, Krivak T. Occult uterine cancer in patients undergoing laparoscopic hysterectomy with morcellation. Western Association of Gynecologic Oncologists, Huntington Beach, CA. 2012
55. Lin J, Hansen K, Beriwal S, Kelley J, Krivak T, Edwards R, Richard S, Olawaiye A, **Zorn K**, Sukumvanich P. Comparison of primary surgery versus definitive radiation for treatment of early endometrial cancer in the elderly population. Western Association of Gynecologic Oncologists, Huntington Beach, CA. 2012

Other Creative Projects

- Lead expert consultant for development of “Understanding Genetics in Gynecologic Cancers”, a Foundation for Women’s Cancer animated video for patients and their families available at <https://www.youtube.com/user/FdtnForWomensCancer>
<https://www.foundatonforwomenscancer.org/gynecologic-cancers/risk-prevention/genetics/> (2018)
- Co-creator of a Genetics Toolkit for the Society of Gynecologic Oncology website in collaboration with the American College of Obstetricians and Gynecologists, the National Society of Genetic Counselors, Bright Pink and Facing Our Risk of Cancer Empowered (FORCE). (2016)
- Edited update to SGO Genetics Toolkit. Available at www.sgo.org/genetics-toolkit (2020)

- Participant in Medscape CME webcast "What does BRCA have to do with it? PARP inhibitors in ovarian cancer" available at www.medscape.org/viewarticle/824444 (2014)
- Organized CME lecture series for clinical management of patients with *BRCA* mutations available at www.UPMCPhysicianResources.com/Cancer (2012)
- Collaborated on the development of "Improving DVT prevention, detection, and treatment in high-risk specialties: DVT medical decision-making in oncology patients" CME lecture for The Research and Education Institute for Texas Health Resources (2008)